Ocular mucous membrane pemphigoid

Dermatologic Therapy

Volumn 15, Issue 4, 2002, Pages 389-396

  Thorne, Jennifer E ^b   Anhalt, Grant J ^b   Jabs, Douglas A ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Bloomberg School of Public Health ^*

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Alkylating agents; Corticosteroids; Cyclophosphamide; Ocular cicatricial pemphigoid treatment; Ocular mucous membrane pemphigoid

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DAPSONE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ALOPECIA; APLASTIC ANEMIA; ASEPTIC NECROSIS; BLADDER DISEASE; BLINDNESS; BONE MARROW SUPPRESSION; BULLOUS SKIN DISEASE; CANCER; CONJUNCTIVA DISEASE; CORTICOSTEROID INDUCED OSTEOPOROSIS; CYTOPENIA; DIABETES MELLITUS; DIARRHEA; DISEASE COURSE; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSLIPIDEMIA; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; HEMATURIA; HEMOLYTIC ANEMIA; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFERTILITY; INFLAMMATION; INSOMNIA; MENTAL INSTABILITY; MOOD DISORDER; NAUSEA; NEUTROPENIA; OBESITY; PEMPHIGOID; PNEUMOCYSTIS PNEUMONIA; REMISSION; REVIEW; SCAR; TERATOGENICITY; THROMBOCYTOPENIA; VOMITING;

EID: 0036968952     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1529-8019.2002.01550.x     Document Type: Review

References (40)

1. Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc 1986: 84: 527-661.
2. Mondino BJ, Brown SI. Ocular cicatricial pemphigoid. Ophthalmology 1981: 88: 95-100.
3. Hardy KM, Perry HO, Pingree GC, et al. Benign mucous membrane pemphigoid. Arch Dermatol 1971: 104: 467-475.
4. Mondino BJ. Cicatricial pemphigoid and erythema multiforme. Ophthalmology 1990: 97: 939-952.
5. Bean SF. Cicatricial pemphigoid: a study of 15 cases. South Med J 1974: 67: 1187-1190.
6. Mondino BJ, Brown SI. Immunosuppressive therapy in ocular cicatricial pemphigoid. Am J Ophthalmol 1983: 96: 453-459.
7. Foster CS, Wilson LA, Ekins MB. Immunosuppressive therapy for progressive ocular cicatricial pemphigoid. Ophthalmology 1982: 89: 340-353.
8. Jabs DA, Anhalt GJ. Cicatricial pemphigoid. In: Provost TT, Farmer ER, eds. Current therapy in dermatology, vol. 2. Toronto: BC Decker, 1988: 56-57.
9. Jones BR. The ocular diagnosis of benign mucous membrane pemphigoid. Proc R Soc Med 1961: 54: 109-110.
10. Herron BE. Immunologic aspects of cicatricial pemphigoid. Am J Ophthalmol 1975: 79: 271-278.
11. Person JR, Rogers RS III. Bullous pemphigoid responding to sulfapyridine and the sulfones. Arch Dermatol 1977: 113: 610-615.
12. Rogers RS III, Seehafer JR, Perry HO. Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone. J Am Acad Dermatol 1982: 6: 215-223.
13. Foster CS. Immunosuppressive therapy for external ocular inflammatory disease. Ophthalmology 1980: 87: 140-150.
14. Brody HJ, Pirozzi DJ. Benign mucous membrane pemphigold. Response to therapy with cyclophosphamide. Arch Dermatol 1977: 113: 1598-1599.
15. Tauber J, Sainz de la Maza M, Foster CS. Systemic chemotherapy for ocular cicatricial pemphigoid. Cornea 1991: 10: 185-195.
16. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000: 130: 492-513.
17. Dave VK, Vickers CFH. Azathioprine in the treatment of muco-cutaneous pemphigoid. Br J Dermatol 1974: 90: 183-186.
18. Dantzig PI. Immunosuppressive and cytotoxic drugs in dermatology. Arch Dermatol 1974: 110: 393-406.
19. van Dijk TJA, van Velde JL. Treatment of pemphigus and pemphigoid with azathioprine. Dermatologica 1973: 147: 179-185.
20. Zurdel J, Aboalchamat B, Zierhut M, et al. Early clinical results with mycophenolate mofetil in immunosuppressive therapy of ocular pemphigoid. Klin Monatsbl Augenheilkd 2001: 218: 222-228.
21. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 1993: 119: 1198-1208.
22. Tamesis RR, Rodriguez A, Christen WG, et al. Systemic drug toxicity trends in immunosuppressive therapy of immune and inflammatory ocular disease. Ophthalmology 1996: 103: 768-775.
23. Zigic TM, Marcoux C, Hungerford DS, Dausereau JV, Stevens MB. Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus. Am J Med 1985: 79: 596-604.
24. Felson DT, Anderson JJ. A cross-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone. Lancet 1987: 1: 902-905.
25. Richards JM, Santiago SM, Klaustermeyer WB. Aseptic necrosis of the femoral head in corticosteroids-treated pulmonary disease. Arch Intern Med 1980: 140: 1473-1475.
26. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998: 339: 292-299.
27. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroids-induced osteoporosis. N Engl J Med 1997: 337: 382-387.
28. Conn Ho, Blitzer BL. Nonassociation of adrenocorticosteroid therapy and peptic ulcer. N Engl J Med 1976: 294: 473-479.
29. Piper JM, Ray WA, Daughterty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal antiinflammatory drugs. Ann Intern Med 1991: 114: 735-740.
30. Kaldor JM, Day NE, Pettersson F, et al. Leukemia following chemotherapy for ovarian cancer. N Engl J Med 1990: 322: 1-6.
31. Radis CD, Kahl LE, Baker GL, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. Arthritis Rheum 1995: 38: 1120-1127.
32. Casciato DA, Scott JL. Acute leukemia following prolonged cytotoxic agent therapy. Medicine 1979: 58: 32-47.
33. Stillwell TJ, Benson RC, DeRemee RA, McDonald TJ, Weiland LH. Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis. Arthritis Rheum 1988: 31: 465-470.
34. Levine LA, Richie JP. Urological complications of cyclophosphamide. J Urol 1989: 141: 1063-1069.
35. Lacki JK, Schochat T, Sobieska M. Immunological studies in patients with rheumatoid arthritis treated with methotrexate or cyclophosphamide. Z Rheumatol 1994: 53: 76-82.
36. Bradley JD, Brandt KD, Katz BP. Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum 1989: 32: 45-53.
37. Singh G, Fries JF, Spitz P, Williams CA. Toxic effects of azathioprine in rheumatoid arthritis. A national postmarketing perspective. Arthritis Rheum 1989: 32: 837-843.
38. Larkin G, Lightman S. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology 1999: 106: 370-374.
39. Raizman MB, Fay AM, Weiss JS. Dapsone-induced neutropenia in patients treated for ocular cicatricial pemphigoid. Ophthalmology 1994: 101: 1805-1807.
40. Neumann R, Tauber J, Foster CS. Remission and recurrence after withdrawal of therapy for ocular cicatricial pemphigoid. Ophthalmology 1991: 98: 858-862.